Salvatore Feo

3.2k citations
76 papers · 2.6k indexed · h-index 29
Topics
S100 Proteins and Annexins (18 papers)RNA and protein synthesis mechanisms (7 papers)RNA modifications and cancer (7 papers)
Partner nations
ItalySpainUnited Kingdom

In The Last Decade

Salvatore Feo

73 papers receiving 2.5k citations

Peers

Salvatore Feo
Comparison fields: 5 of 129
  • Molecular Biology 1.6k
  • Cancer Research 576
  • Oncology 417
  • Immunology 283
  • Genetics 184
Replace Nicole Thomasset with:
Nicole Thomasset France
Karel Souček Czechia
Paloma Pérez Spain
Maja Tomičić Germany
Marcel H.J. Ruiters Netherlands
Karin Roberg Sweden
Jesús Espada Spain
Guo‐fu Hu United States
Yuan Chen China
Kai Xu China
Salvatore Feo relative to Nicole Thomasset France Nicole Thomasset's profile →
Citations per field
00.5×1.5×2.5×
Nicole Thomasset · 1×
Citations per year

Countries citing papers authored by Salvatore Feo

Since Specialization
Citations

This map shows the geographic impact of Salvatore Feo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Salvatore Feo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Salvatore Feo more than expected).

Fields of papers citing papers by Salvatore Feo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Salvatore Feo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Salvatore Feo. The network helps show where Salvatore Feo may publish in the future.

Co-authorship network of co-authors of Salvatore Feo

This figure shows the co-authorship network connecting the top 25 collaborators of Salvatore Feo. A scholar is included among the top collaborators of Salvatore Feo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Salvatore Feo. Salvatore Feo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 4
3 15
4 12
5 27
6 1
7 5
8 31
9 11
10 19
11 35
12 22
13 233
14 56
15 8
16 17
17 15
18 30
19 35
20 18

About Salvatore Feo

Salvatore Feo is a scholar working on Molecular Biology, Immunology and Allergy and Cell Biology, having authored 76 papers that have together received 2.6k indexed citations. Recurring topics across this work include S100 Proteins and Annexins (18 papers), RNA and protein synthesis mechanisms (7 papers) and RNA modifications and cancer (7 papers). The work is most often cited by research in Cancer Research (576 citations), Molecular Biology (1.6k citations) and Oncology (417 citations). Salvatore Feo has collaborated with scholars based in Italy, Spain and United Kingdom. Frequent co-authors include Agata Giallongo, Patrizia Cancemi, Rosa Passantino, Miriam Buttacavoli, Eugenia Piddini, Giovanna Barbieri, Daniele Oliva, Giovanni Perconti, Mike Fried and Giulio Cossu. Their work appears in journals such as Nature, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026